Research, based at the Department of Ophthalmology at the University of Kiel, Germany, has indicated that aflibercept and bevacizumab may interfere with the physiology of RPE cells. The in-vitro lab-based study assessed the impact of aflibercept and bevacizumab in a primary porcine RPE cell system and results suggested that when clinically relevant concentrations were used, aflibercept and bevacizumab displayed a statistically significant effect on wound healing compared with control (control 87.3±8.4% closure, aflibercept 500 mg/mL 70.3±10.3% closure, p<0.01; bevacizumab 250 mg/mL 80.7±6.8% closure, p<0.05).
Results of small cell study suggests aflibercept and bevacizumab may impair wound healing capability of porcine RPE cells
- by swdadmin